OSLO, Norway, April 30, 2020 /PRNewswire/ -- Targovax
ASA (OSE: TRVX) announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific
Officer (CSO). He will play a leading role in driving research
strategy and pipeline expansions, particularly the scientific and
mechanistic aspects of early clinical work. Dr Levitsky will serve
as a member of Targovax's management team.
Dr Levitsky is a seasoned internationally recognized expert in
immunology, oncology, T-cell immunotherapy and immuno-oncology with
in-depth knowledge of preclinical, translational and early stage
clinical drug development. He brings extensive experience in
pre-clinical drug development of protein-based biologics and small
molecules. Dr Levitsky is a medical doctor with a PhD in Virology
and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his
career as an academic research scientist, including Associate
Professor positions at the Karolinska
Institute in Sweden and the
Johns Hopkins University School of
Medicine in the US. Before joining Targovax Dr Levitsky
served as Tumor Immunology Leader and Senior Principal Scientist
with Roche in Zurich, and his most
recent position has been VP, Head of Oncology Research at Molecular
Partners, Zurich, Switzerland.
Dr Levitsky is the author of numerous scientific
publications.
Øystein Soug, CEO, commented: "It is with great
enthusiasm that we welcome Dr Levitsky to Targovax! With his broad
and deep oncology experience and with his background as a
virologist, he will bring important scientific leadership to
Targovax. As we progress towards several important data read-outs
and move forward with our pipeline expansion initiatives, Victor
will play an instrumental role in shaping the future for
Targovax."
Dr Levitsky added: "I am very excited to be joining
Targovax at what is clearly an important stage for the company. The
oncolytic virus and mutant RAS technology platforms have clear
potential to benefit cancer patients through current and multiple
novel strategies, and I look forward to joining the strong team at
Targovax to help build the scientific framework for bringing these
promising products to patients."
Dr Levitsky will commence as CSO on 4th May.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa-appoints-dr-victor-levitsky-as-chief-scientific-officer,c3101140
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-appoints-dr-victor-levitsky-as-chief-scientific-officer-301049920.html
SOURCE Targovax